Finance entity
Every one of those 2 sits in a single category, markets. Needham is most often covered alongside Citi, which appears in 1 of these 2 stories. Across a 14-day span, the pace is roughly 1 story per week. The 6 average consequence score is below the beat benchmark of 6.2 in the same window.
Last mentioned: Mar 10, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 2 sits in a single category, markets. Needham is most often covered alongside Citi, which appears in 1 of these 2 stories. Across a 14-day span, the pace is roughly 1 story per week. The 6 average consequence score is below the beat benchmark of 6.2 in the same window. Source depth averages 2.5 original sources per story, versus 2.6 across the same-window beat baseline. This profile follows 2 Finance stories mentioning Needham across the period from February 25, 2026 to March 10, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 996 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Needham. Shared-story counts are live from our verified record — not editorial picks.
Product Transition
Hims & Hers expected to fully phase out compounded GLP-1s in favor of branded Ozempic.
Strategic Settlement
Hims & Hers and Novo Nordisk announce a distribution partnership and lawsuit dismissal.
Market Surge
HIMS stock skyrockets 41% with record-breaking trading volume.
Restructuring Announced
The company officially announces job cuts and a broader organizational restructure to cut costs.
Price Target Cut
Needham slashes its price target for DraftKings to $35, reflecting a more cautious outlook.
Stock Plunge
DKNG shares hit 'oversold' territory after a multi-day selloff following the earnings report.
Earnings Miss
DraftKings reports disappointing quarterly results and lowers its future revenue guidance.
Legal Friction
Novo Nordisk files patent infringement lawsuits against telehealth providers selling compounded GLP-1s.
Hims & Hers Health shares skyrocketed following a strategic partnership with Novo Nordisk to distribute branded GLP-1 medications, effectively ending a high-stakes patent dispute. The agreement shifts the telehealth provider's weight-loss strategy from controversial compounded versions to FDA-approved Ozempic, significantly de-risking its long-term growth profile.
DraftKings has announced a workforce reduction and organizational restructuring to align its cost structure with a revised revenue outlook. The move follows a disappointing February earnings report that saw the stock plunge and analysts lower price targets amid concerns over long-term profitability.
Needham is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
